S455 Efficacy and Safety of the Selective Sphingosine 1-Phosphate Receptor Modulator, Etrasimod, in Adult Patients With Eosinophilic Esophagitis: Primary Results From the Phase 2 VOYAGE Study
Evan S. Dellon(University of North Carolina at Chapel Hill), Ikuo Hirano(Northwestern University), Chinyu Su(Pfizer (United States)), Albert J. Bredenoord(Amsterdam Neuroscience), Luc Biedermann(University of Zurich), Fabio Cataldi(Pfizer (United States)), Thai Nguyen-Cleary(Pfizer (United States)), Margaret H. Collins(Cincinnati Children's Hospital Medical Center), Natalie V. Springveld(Pfizer (Switzerland)), Jin Yu(Pfizer (United States)), Wenjin Wang(Shanghai Jiao Tong University), Márjori Dulcine, John Woolcott(Pfizer (United States)), Hanzhe Zheng(Pfizer (United States)), Hamish Philpott(The University of Adelaide)
Cited by 10
Related Papers
Eosinophilic esophagitis: Updated consensus recommendations for children and adults
|Journal of Allergy and Clinical Immunology|2011|2.1k
Burden of Gastrointestinal Disease in the United States: 2012 Update
|Gastroenterology|2012|2k
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018
|Gastroenterology|2018|1.7k
Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference
|Gastroenterology|2018|1.1k
Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States
|Gastroenterology|2015|996